Quinn Opportunity Partners LLC Cassava Sciences Inc Transaction History

Quinn Opportunity Partners LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$36.77 - $90.91 $220,620 - $545,460	-6,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $125,370 - $405,900	3,000 Added 100.0%	6,000 $372,000
Q2 2021 Aug 16, 2021	SELL	$32.15 - $89.72 $321,500 - $897,200	-10,000 Reduced 76.92%	3,000 $256,000
Q1 2021 May 13, 2021	SELL	$7.09 - $87.95 $716,090 - $8.88 Million	-101,000 Reduced 88.6%	13,000 $584,000
Q4 2020 Feb 11, 2021	BUY	$6.79 - $12.25 $224,070 - $404,250	33,000 Added 40.74%	114,000 $777,000
Q3 2020 Nov 16, 2020	BUY	$2.86 - $11.51 $231,660 - $932,310	81,000 New	81,000 $932,000
Q2 2020 Aug 14, 2020	SELL	$2.04 - $9.64 $72,801 - $344,022	-35,687 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$3.26 - $9.65 $116,339 - $344,379	35,687 New	35,687 $147,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $110M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Quinn Opportunity Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Quinn Opportunity Partners LLC with notifications on news.